levodopa has been researched along with adenosine in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (13.04) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 10 (43.48) | 29.6817 |
| 2010's | 5 (21.74) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Boer, PH; Fekkes, D; Korf, J | 1 |
| Pugsley, TA; Stewart, SF | 1 |
| Breese, GR; Criswell, H; Mueller, RA | 1 |
| Di Chiara, G; Fenu, S; Morelli, M; Pinna, A | 1 |
| Kanda, T; Nakamura, J; Shimada, J; Shiozaki, S; Suzuki, F | 1 |
| Ichikawa, S; Kitamura, S; Kuwana, Y; Nakamura, J; Shiozaki, S; Yamada, K | 1 |
| Arakawa, K; Koga, M; Noda, K; Sasaguri, M; Takezako, T; Tsuji, E | 1 |
| Müller, T | 2 |
| Kulkarni, SK; Singh, A | 1 |
| Chen, JF | 1 |
| Hirose, S; Kaneko, S; Okada, M; Yoshida, S; Zhu, G | 1 |
| Agnati, LF; Ferré, S; Franco, R; Fuxe, K; Hockemeyer, J; Leo, G; Lluis, C; Martínez, E; Vergoni, AV | 1 |
| Cristalli, G; Morelli, M; Pinna, A; Volpini, R | 1 |
| Aguilar, E; Bové, J; Cortés, R; Marin, C; Mengod, G; Serrats, J | 1 |
| Jenner, P; Ramsay Croft, N; Rose, S | 1 |
| Ahmed, I; Bose, SK; Brooks, DJ; Pavese, N; Ramlackhansingh, AF; Turkheimer, FE | 1 |
| Aradi, SD; Hauser, RA; LeWitt, PA; Rascol, O | 1 |
| Airas, L; Helin, S; Joutsa, J; Parkkola, R; Rinne, JO; Rissanen, E; Tuisku, J; Waggan, I | 1 |
3 review(s) available for levodopa and adenosine
| Article | Year |
|---|---|
Non-dopaminergic drug treatment of Parkinson's disease.
Topics: Adenosine; Adrenergic alpha-Antagonists; Body Weight; Cholinergic Antagonists; Homocysteine; Humans; Levodopa; Methionine; N-Methylaspartate; Parkinson Disease; Piperidines; Serotonin Receptor Agonists | 2001 |
The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Brain; Caffeine; Dopamine; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Receptor, Adenosine A2A; Treatment Failure | 2003 |
Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Blood-Brain Barrier; Disease Models, Animal; Dopamine Agonists; Dyskinesias; Half-Life; Humans; Levodopa; Parkinson Disease; Purines; Treatment Outcome | 2013 |
20 other study(ies) available for levodopa and adenosine
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
CYCLIC AMP/*SECRETl cyclic AMP into push-pull perfusates in freely moving rats.
Topics: Adenosine; Animals; Brain; Cerebral Ventricles; Clonidine; Cyclic AMP; Dopamine; Histamine; Isoproterenol; Levodopa; Male; Norepinephrine; Perfusion; Rats; Receptors, Adrenergic; Serotonin | 1976 |
Increase of rat serum prolactin by adenosine analogs and their blockade by the methylxanthine aminophylline.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); alpha-Methyltyrosine; Aminophylline; Animals; Bromocriptine; Corpus Striatum; Haloperidol; In Vitro Techniques; Levodopa; Male; Methyltyrosines; Phenylisopropyladenosine; Pituitary Gland, Anterior; Prolactin; Rats; Rats, Inbred Strains; Receptors, Cell Surface; Receptors, Purinergic | 1985 |
Assessment of purine-dopamine interactions in 6-hydroxydopamine-lesioned rats: evidence for pre- and postsynaptic influences by adenosine.
Topics: Adenosine; Animals; Female; Hydroxydopamines; Hypoxanthine Phosphoribosyltransferase; Lesch-Nyhan Syndrome; Levodopa; Motor Activity; Oxidopamine; Pregnancy; Purines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Purinergic; Theophylline | 1988 |
Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adenosine; Animals; Antihypertensive Agents; Autoradiography; Basal Ganglia; Benserazide; Binding Sites; Dopamine Agents; Ergolines; Levodopa; Male; Neural Pathways; Neurons; Oxidopamine; Phenethylamines; Quinolinic Acid; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Purinergic P1; Stereotyped Behavior | 1994 |
KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.
Topics: Adenosine; Administration, Oral; Animals; Antihypertensive Agents; Benserazide; Catalepsy; Dose-Response Relationship, Drug; Drug Synergism; Haloperidol; Levodopa; Male; Mice; Phenethylamines; Purinergic Antagonists; Xanthines | 1994 |
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine; Animals; Antiparkinson Agents; Antipsychotic Agents; Caffeine; Catalepsy; Dopamine Agents; Hypokinesia; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Phenethylamines; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purines; Reserpine; Theophylline | 1999 |
Adenosine activates aromatic L-amino acid decarboxylase activity in the kidney and increases dopamine.
Topics: Adenosine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Benzazepines; Diuresis; Dopamine; Enzyme Activation; Kidney; Levodopa; LLC-PK1 Cells; Male; Natriuresis; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Swine | 2001 |
Role of adenosine in drug-induced catatonia in mice.
Topics: Adenosine; Animals; Antiparkinson Agents; Brain; Carbidopa; Catatonia; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Injections, Intraperitoneal; Levodopa; Male; Mice; Motor Activity; Perphenazine | 2002 |
Both 3,4-dihydroxyphenylalanine and dopamine releases are regulated by Ca2+-induced Ca2+ releasing system in rat striatum.
Topics: Adenosine; Analysis of Variance; Animals; Calcium; Calcium Channels; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Electrochemistry; Inositol 1,4,5-Trisphosphate; Inositol 1,4,5-Trisphosphate Receptors; Levodopa; Macrocyclic Compounds; Male; Microdialysis; Oxazoles; Potassium; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Ruthenium Red; Ryanodine; Ryanodine Receptor Calcium Release Channel; Time Factors; Verapamil | 2004 |
Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Therapy, Combination; Dyskinesias; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinson Disease; Phenethylamines; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2004 |
New adenosine A2A receptor antagonists: actions on Parkinson's disease models.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Binding, Competitive; Catalepsy; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drug Synergism; Levodopa; Male; Molecular Structure; Parkinson Disease; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Tritium | 2005 |
Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adenosine; Adrenergic Agents; Animals; Caffeine; Corpus Striatum; Dynorphins; Dyskinesias; Enkephalins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; RNA, Messenger | 2006 |
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Exploratory Behavior; Levodopa; Male; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Sympatholytics; Triazoles | 2007 |
Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Aged; Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Pyrazoles; Pyrimidines; Receptor, Adenosine A2A | 2011 |
The challenge of developing adenosine A
Topics: Adenosine; Animals; Antiparkinson Agents; Benzothiazoles; Humans; Levodopa; Parkinson Disease; Purines | 2020 |
Adenosine A
Topics: Adenosine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Receptor, Adenosine A2A | 2023 |